α-Acetylhomophthalic anhydride | 2848-28-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: α-Acetylhomophthalic anhydride
• 英文别名: 4-acetyl-1,3-isochromandione；4-acetylisochroman-1,3-dione；4-acetyl-isochroman-1,3-dione；4-Acetyl-homophthalsaeureanhydrid；4-Acetylisochroman-1,3-dion；4-Acetyl-1H-2-benzopyran-1,3(4H)-dione；4-acetyl-4H-isochromene-1,3-dione
• CAS: 2848-28-4
• 化学式: C₁₁H₈O₄
• 分子量: 204.182
• InChiKey: MECJTMNEUMDNBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  α-Acetylhomophthalic anhydride 在 盐酸 作用下， 以 水 为溶剂， 反应 9.0h， 生成 2-甲基异喹啉-1,3(2H,4H)-二酮
  参考文献：
  名称：

  Datta, D.; Tirodkar, R. B.; Usgaonkar, R. N., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1980, vol. 19, # 8, p. 641 - 643

  摘要：

  DOI：
• 作为产物：
  描述：

  邻羧基苯乙酸 在 吡啶 、 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 17.25h， 生成 α-Acetylhomophthalic anhydride
  参考文献：
  名称：

  Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis

  摘要：

  Bromodomain (BRDs) are epigenetic interaction domains currently recognized as emerging drug targets for development of anticancer or anti-inflammatory agents. In this study, development of a selective ligand of the fifth BRD of polybromo protein-1. (PB1(S)) related to switch/sucrose nonfermenting (SWI/SNF) chromatin remodeling complexes is presented. A compound collection was evaluated by consensus virtual screening and a hit was identified. The biophysical study of protein-ligand interactions was performed using X-ray crystallography and isothermal titration calorimetry. Collective data supported the hypothesis that affinity improvement could be achieved by enhancing interactions of the complex with the solvent. The derived SAR along with free energy calculations and a consensus hydration analysis using WaterMap and SZmap algorithms guided rational design of a set of novel analogues. The most potent analogue demonstrated high affinity of 3.3 mu M and an excellent selectivity profile, thus comprising a promising lead for the development of chemical probes targeting PB1(5).

  DOI：

  10.1021/acs.jmedchem.6b00355

文献信息

• [EN] USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS<br/>[FR] UTILISATION D'INHIBITEURS DE DDX3 EN TANT QU'AGENTS ANTIPROLIFÉRATIFS
  申请人：AZIENDA OSPEDALIERA UNIV SENESE

  公开号：WO2017162834A1

  公开（公告）日：2017-09-28

  The present invention refers to compounds of formula I or II endowed with DDX3 inhibitory activity, relative pharmaceutical compositions and their use as antihyperproliferative agents. (I) or (II)

  这项发明涉及具有DDX3抑制活性的I或II式化合物，相关的药物组合物以及它们作为抗高增殖剂的用途。(I)或(II)
• [EN] 1-ARYL-4-SUBSTITUTED ISOQUINOLINES<br/>[FR] ISOQUINOLINES 1-ARYL-4-SUBSTITUEES
  申请人：NEUROGEN CORP

  公开号：WO2005110991A1

  公开（公告）日：2005-11-24

  1-Aryl-4-substituted isoquinolines analogues of Formula (I) and Formula (II) are provided, as follows : wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula (I) and (II) bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 1-aryl-4-substituted isoquinolines, which are useful as probes for the localization of C5a receptors.

  提供了Formula (I)和Formula (II)的1-芳基-4-取代异喹啉类似物，具体如下：其中R1、R2、R3、R8、R9、A和Ar在此处定义。这些化合物是C5a受体的配体。Formula (I)和(II)的优选化合物与C5a受体结合亲和力高，并在C5a受体上表现为中性拮抗剂或逆向激动剂活性。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物治疗各种炎症、心血管和免疫系统疾病的用途。此外，本发明提供了标记的1-芳基-4-取代异喹啉，可用作C5a受体的定位探针。
• [EN] HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS<br/>[FR] INHIBITEURS D'HÉLICASE DDX3 HUMAINE COMME AGENTS THÉRAPEUTIQUES
  申请人：AZIENDA OSPEDALIERA UNIV SENESE

  公开号：WO2016128541A1

  公开（公告）日：2016-08-18

  The present invention refers to compounds endowed with RNA helicase DDX3 inhibitory activity of formula I and II and their therapeutic use, in particular for the treatment of viral diseases.

  本发明涉及具有RNA解旋酶DDX3抑制活性的化合物I和II的公式及其治疗用途，特别是用于治疗病毒性疾病。
• The design, synthesis and structure–activity relationships of 1-aryl-4-aminoalkylisoquinolines: A novel series of CRF-1 receptor antagonists
  作者：Taeyoung Yoon、Stéphane De Lombaert、Robbin Brodbeck、Michael Gulianello、Jayaraman Chandrasekhar、Raymond F. Horvath、Ping Ge、Mark T. Kershaw、James E. Krause、John Kehne、Diane Hoffman、Darío Doller、Kevin J. Hodgetts

  DOI：10.1016/j.bmcl.2007.12.050

  日期：2008.2

  The design, synthesis and structure-activity relationships of a novel series of CRF-1 receptor antagonist, the 1-aryl-4-alkylaminoisoquinolines, is described. The effects of substitution on the aromatic ring, the amino group and the isoquinoline core on CRF-1 receptor binding were investigated.

  描述了一系列新型CRF-1受体拮抗剂1-芳基-4-烷基氨基异喹啉的设计，合成和构效关系。研究了取代对芳环，氨基和异喹啉核心对CRF-1受体结合的影响。
• 1-aryl-4-substituted isoquinolines
  申请人：Lee Kyungae

  公开号：US20070249665A1

  公开（公告）日：2007-10-25

  1-aryl-4-substituted isoquinoline or 1-aryl-3,4-disubstituted isoquinoline analogues of Formula I and Formula II, as follows: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5 a receptors. Preferred compounds of Formula I and II bind to C5 a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5 a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 1-aryl-4-substituted isoquinolines or 1-aryl-3,4-disubstituted isoquinolines, which are useful as probes for the localization of C5 a receptors.

  以下为翻译结果： 本发明提供了公式I和公式II的1-芳基-4-取代异喹啉或1-芳基-3,4-二取代异喹啉类似物，其中R1、R2、R3、R8、R9、A和Ar在此定义。这些化合物是C5a受体的配体。公式I和II的优选化合物具有高亲和力结合C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物治疗多种炎症、心血管和免疫系统疾病的用途。此外，本发明还提供了标记的1-芳基-4-取代异喹啉或1-芳基-3,4-二取代异喹啉，可用作定位C5a受体的探针。